Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have an intrauterine pregnancy consistent with gestational age less than 71 days;~* Be able to understand and willing to sign a consent form;~* Be eligible for medical abortion according to the clinician's assessment;~* Be able to return to the clinic and able to contact study staff or emergency medical services, if needed;~* Be willing to provide an address and/or telephone number for purposes of follow-up;~* Agree to comply with the study procedures and visit schedule.~Exclusion Criteria:~* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;~* Chronic renal failure;~* Concurrent long-term corticosteroid therapy;~* History of allergy to mifepristone, or misoprostol or another prostaglandin;~* History of hemorrhagic disorders or concurrent anticoagulant therapy;~* History of inherited porphyrias;~* Intrauterine device in place (must be removed before mifepristone is administered).

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Women seeking medical abortion (Type: None): Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.

Based on this trial design, predict the completion outcome and termination type (if applicable).